Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Cholangiocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pharyngeal Neoplasms 1Oropharyngeal Neoplasms 1Oligometastatic Prostate Cancer 1Mouth Neoplasms 1Melanoma 1Lung Diseases 1Locally Advanced Pancreatic Cancer 1Locally Advanced Cervical Cancer 1Liver Neoplasms 1Liposarcoma 1Laryngeal Neoplasms 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Nivolumab 74Sunitinib 73pembrolizumab 49Everolimus 39Sorafenib 36Bevacizumab 36Axitinib 36cabozantinib 35Radiosurgery 33Ipilimumab 33pazopanib 32Magnetic Resonance Spectroscopy 27Interleukin-2 27aldesleukin 23Specimen Handling 22Cyclophosphamide 21lenvatinib 20fludarabine phosphate 17Radiotherapy 16Interferon-alpha 15Peripheral Blood Stem Cell Transplantation 14Gemcitabine 14Biopsy 14temsirolimus 13Nephrectomy 13durvalumab 11Immunohistochemistry 11CTLA-4 Antigen 11Blood Specimen Collection 11Capecitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Renal Cell × zimberelimab × Clear all
NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡